Search

• Update - GSK Consumer Healthcare

  Media

  GlaxoSmithKline (GSK) plc today confirms it has received three unsolicited, conditional and non-binding proposals from Unilever plc

  https://www.gsk.com/en-gb/media/press-releases/update-gsk-consumer-healthcare/

  First published: 15 January 2022

• China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus

  Media

  China’s National Medical Products Administration has approved a two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years.

  https://www.gsk.com/en-gb/media/press-releases/china-approves-cervarix-two-dose-vaccine-schedule-for-girls-aged-9-to-14-against-certain-types-of-cancer-causing-human-papillomavirus/

  First published: 27 May 2022

• Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer

  Media

  Regulatory submissions based on the trial results are planned for the first half of 2023.

  https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 02 December 2022

• GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

  Media

  GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

  https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/

  First published: 22 April 2014

• ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection

  Media

  ViiV Healthcare, Pfizer Inc. and Shionogi Limited with Janssen for cabotegravir and rilpivirine for the treatment of HIV-1 infection.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-1-infection/

  First published: 07 January 2016

• GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint

  Media

  GSK and THRX today announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001)

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-post-hoc-analysis-of-anoro-ellipta-data-assessing-markers-of-copd-deterioration-compared-to-tiotropium-or-placebo-using-a-novel-composite-endpoint/

  First published: 27 September 2015

• GSK and Merck to study immunotherapy combination as potential cancer treatment

  Media

  Phase I human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda®

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment/

  First published: 03 November 2015

• GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries

  Media

  GSK announced that EMA has granted marketing authorisation for Nucala® as an add-on treatment for severe refractory eosinophilic asthma

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries/

  First published: 02 December 2015

• GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD

  Media

  GSK and THRX today announced positive results from two phase III studies.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-data-from-two-studies-evaluating-the-efficacy-and-safety-of-incruse-ellipta-when-added-to-relvar-breo-ellipta-in-patients-with-copd/

  First published: 11 June 2014

• GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)

  Media

  GSK announced today that the FDA has approved Mekinist® (trametinib) for use with Tafinlar® (dabrafenib) for the treatment melanoma

  https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/

  First published: 09 January 2014